BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 32373065)

  • 1. Mutation of
    Su L; Zhang X; Zheng L; Wang M; Zhu Z; Li P
    Front Endocrinol (Lausanne); 2020; 11():189. PubMed ID: 32373065
    [No Abstract]   [Full Text] [Related]  

  • 2. Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas.
    Wang P; Dong Q; Zhang C; Kuan PF; Liu Y; Jeck WR; Andersen JB; Jiang W; Savich GL; Tan TX; Auman JT; Hoskins JM; Misher AD; Moser CD; Yourstone SM; Kim JW; Cibulskis K; Getz G; Hunt HV; Thorgeirsson SS; Roberts LR; Ye D; Guan KL; Xiong Y; Qin LX; Chiang DY
    Oncogene; 2013 Jun; 32(25):3091-100. PubMed ID: 22824796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
    Grassian AR; Pagliarini R; Chiang DY
    Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
    Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
    Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
    Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
    Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
    Kipp BR; Voss JS; Kerr SE; Barr Fritcher EG; Graham RP; Zhang L; Highsmith WE; Zhang J; Roberts LR; Gores GJ; Halling KC
    Hum Pathol; 2012 Oct; 43(10):1552-8. PubMed ID: 22503487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
    Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
    Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping.
    Borger DR; Tanabe KK; Fan KC; Lopez HU; Fantin VR; Straley KS; Schenkein DP; Hezel AF; Ancukiewicz M; Liebman HM; Kwak EL; Clark JW; Ryan DP; Deshpande V; Dias-Santagata D; Ellisen LW; Zhu AX; Iafrate AJ
    Oncologist; 2012; 17(1):72-9. PubMed ID: 22180306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutation correlates with a beneficial prognosis and suppresses tumor growth in IHCC.
    Wang J; Zhang ZG; Ding ZY; Dong W; Liang HF; Chu L; Zhang BX; Chen XP
    J Surg Res; 2018 Nov; 231():116-125. PubMed ID: 30278918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum Sensitivity in
    Doroshow DB; Wei W; Mehrotra M; Sia D; Eder JP; Bindra R; Houldsworth J; LoRusso P; Walther Z
    Cancer Invest; 2023 Sep; 41(7):646-655. PubMed ID: 37505929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Altered Expression of Oxidative Metabolism Related Genes in Cholangiocarcinomas.
    Aukkanimart R; Boonmars T; Juasook A; Sriraj P; Boonjaraspinyo S; Wu Z; Laummuanwai P; Pairojkul C; Khuntikeo N; Rattanasuwan P
    Asian Pac J Cancer Prev; 2015; 16(14):5875-81. PubMed ID: 26320466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma.
    Zhu Y; Kwong LN
    Cancer Discov; 2022 Mar; 12(3):604-605. PubMed ID: 35257150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.
    Rimini M; Fabregat-Franco C; Persano M; Burgio V; Bergamo F; Niger M; Scartozzi M; Rapposelli IG; Aprile G; Ratti F; Pedica F; Verdaguer H; Rizzato M; Nichetti F; Lai E; Cappetta A; Macarulla T; Fassan M; De Braud F; Pretta A; Simionato F; De Cobelli F; Aldrighetti L; Fornaro L; Cascinu S; Casadei-Gardini A
    Target Oncol; 2023 Jan; 18(1):139-145. PubMed ID: 36689074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
    Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
    BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Crispo F; Pietrafesa M; Condelli V; Maddalena F; Bruno G; Piscazzi A; Sgambato A; Esposito F; Landriscina M
    Molecules; 2020 Aug; 25(16):. PubMed ID: 32824685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahepatic cholangiocarcinomas with IDH1/2 mutation-associated hypermethylation at selective genes and their clinicopathological features.
    Lee K; Song YS; Shin Y; Wen X; Kim Y; Cho NY; Bae JM; Kang GH
    Sci Rep; 2020 Sep; 10(1):15820. PubMed ID: 32978444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.
    Peraldo-Neia C; Ostano P; Cavalloni G; Pignochino Y; Sangiolo D; De Cecco L; Marchesi E; Ribero D; Scarpa A; De Rose AM; Giuliani A; Calise F; Raggi C; Invernizzi P; Aglietta M; Chiorino G; Leone F
    BMC Genomics; 2018 Jun; 19(1):440. PubMed ID: 29871612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Immunogenomic Profiling of
    Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
    JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
    Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
    Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-Eleven Translocation 1 Promotes Malignant Progression of Cholangiocarcinoma With Wild-Type Isocitrate Dehydrogenase 1.
    Bai X; Zhang H; Zhou Y; Nagaoka K; Meng J; Ji C; Liu D; Dong X; Cao K; Mulla J; Cheng Z; Mueller W; Bay A; Hildebrand G; Lu S; Wallace J; Wands JR; Sun B; Huang CK
    Hepatology; 2021 May; 73(5):1747-1763. PubMed ID: 32740973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.